Skip to content
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
SV
Press releases
All
News
Regulatory
MAR
All
All
News
Regulatory
MAR
November 27, 2023
New issue of Ingeneious, no 5 2023
Read More
November 10, 2023
Interim report January – September 2023 for CombiGene AB (publ)
Read More
October 31, 2023
CombiGene chooses Charles River as preclinical toxicology partner for COZY01 pain project
Read More
October 26, 2023
CombiGene and Zyneyro choose initial indication in the COZY01 pain project
Read More
October 25, 2023
CombiGene AB (publ): Nominating committee
Read More
October 14, 2023
Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene
Read More
September 15, 2023
CombiGene chooses CDMO partner for the COZY01 pain project
Read More
September 8, 2023
New issue of Ingeneious, no 4 2023
Read More
Load More
Search
Search
2022
November 11, 2022
Interim report January – September 2022 for CombiGene AB (publ)
November 10, 2022
CombiGene AB (publ): Nominating committee
November 4, 2022
New issue of Ingeneious, no 3 2022
September 27, 2022
CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO
August 25, 2022
Interim report January – June 2022 for CombiGene AB (publ)
June 23, 2022
GeneNova collaboration to develop adeno-associated virus based gene therapies
June 22, 2022
New issue of Ingeneious, no 2:3 2022
June 16, 2022
New issue of Ingeneious, no 2:2 2022
Load more
2021
December 16, 2021
CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe
November 15, 2021
CombiGene AB (publ): Nominating committee
November 12, 2021
Interim report January – September for CombiGene AB (publ)
November 1, 2021
CombiGene’s Horizon 2020 project successfully completed
October 18, 2021
New issue of Ingeneious no 3 2021
October 12, 2021
CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01
August 25, 2021
CombiGene applies for international patent protection for the vectors developed within the CGT2 project
August 20, 2021
Interim report January – June 2021 for CombiGene AB (publ)
Load more
2020
December 14, 2020
With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01
December 4, 2020
CombiGene’s research is recognized internationally after careful scientific review
December 2, 2020
CombiGene’s warrants of series TO4 and TO5 utilized to 98.4 per cent
November 25, 2020
CombiGene, together with gene therapy manufacturer Viralgen, has successfully completed the first large-scale production of CG01
November 24, 2020
Major shareholders and management demonstrate their faith in CombiGene by participating in the warrants of series TO4 and TO5
November 23, 2020
CombiGene signs agreement with British Neurochase for optimized administration of CG01, a gene therapy developed for treatment of focal epilepsy
November 19, 2020
CombiGene AB (publ): Nominating committee
November 18, 2020
Horizon 2020 continues to invest in CombiGene´s epilepsy project
Load more
2019
December 19, 2019
Study in human brain tissue shows that NPY can suppress epileptic activity via Y2-receptor activation
December 16, 2019
New issue of CombiGenes newsletter Ingeniouis
November 26, 2019
CombiGene’s Chairman and CEO increase their shareholdings in the company
November 20, 2019
Professor Merab Kokaia’s proof-of-concept study has been published in Molecular Therapy: Methods & Clinical Development
November 18, 2019
CombiGene receives a second payment of EUR 1.21 million from Horizon 2020
November 13, 2019
Outcome of exercise of warrants in CombiGene
October 24, 2019
CombiGene carries out a directed new issue of shares to Lipigon Pharmaceuticals
October 16, 2019
CombiGene launches new website
Load more
2018
December 17, 2018
CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018
December 17, 2018
CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018
December 14, 2018
Ingeneious #5 2018, News from CombiGene
December 14, 2018
New issue of CombiGene’s newsletter Ingenious
December 14, 2018
CombiGene featured in an article in Nature, one of the world’s leading scientific journals
December 14, 2018
CombiGene featured in a major article in Nature, one of the world’s leading scientific journals
December 11, 2018
January 29, Lund Aktiedagen
December 10, 2018
April 4, National ATMP Conference 2019, Göteborg
Load more
2017
December 22, 2017
Another gene therapy product was approved by the FDA
December 14, 2017
Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01
December 7, 2017
Initial data from the long-term study on CombiGene’s candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures.
November 30, 2017
Ingeneious #4 2017, News from CombiGene
November 29, 2017
Interview with Merab Kokaia concerning CombiGene’s long-term study
November 23, 2017
CombiGene attended “Advanced Therapies Investor Day” in London
November 8, 2017
CombiGene has today launched its new website www.combigene.com
November 1, 2017
Interim Report January-September 2017
Load more
